NMPA Approval

Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets (Ⅳ)

Approval Number

国药准字H20254140

Company浙江华海药业股份有限公司

Registration Date

May 13, 2025

Drug Information

Generic Name

达格列净二甲双胍缓释片(Ⅳ)

Dosage Form

片剂

Strength

每片含达格列净10mg（按C₂₁H₂₅ClO₆计）和盐酸二甲双胍500mg

Drug Type

化学药品

Registration Date

May 13, 2025

Company Information

Applicant Company

Company Name浙江华海药业股份有限公司

Company Address

浙江省临海市汛桥

Manufacturing Company

Company Name浙江华海药业股份有限公司

Company Address

浙江省临海市汛桥

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.

达格列净二甲双胍缓释片(Ⅳ) - NMPA 批准文号 | MedPath